These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27358486)

  • 1. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
    Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
    Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
    Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
    Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
    Zengin T; Önal-Süzek T
    BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
    Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
    Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
    Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
    Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
    Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.
    Karlsson A; Jönsson M; Lauss M; Brunnström H; Jönsson P; Borg Å; Jönsson G; Ringnér M; Planck M; Staaf J
    Clin Cancer Res; 2014 Dec; 20(23):6127-40. PubMed ID: 25278450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method.
    Cai Q; He B; Xie H; Zhang P; Peng X; Zhang Y; Zhao Z; Wang X
    Cancer Med; 2020 Oct; 9(20):7488-7502. PubMed ID: 32860318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
    Guo T; Zhao S; Li Z; Li F; Li J; Gu C
    Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An individualized gene expression signature for prediction of lung adenocarcinoma metastases.
    Qi L; Li T; Shi G; Wang J; Li X; Zhang S; Chen L; Qin Y; Gu Y; Zhao W; Guo Z
    Mol Oncol; 2017 Nov; 11(11):1630-1645. PubMed ID: 28922552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.
    Chen YC; Lin MC; Hsiao CC; Zheng YX; Chen KD; Sung MT; Chen CJ; Wang TY; Lin YY; Chang HC; Chen YM; Chang JC
    Oncotarget; 2017 Jul; 8(28):45710-45724. PubMed ID: 28498804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
    Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
    Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
    Chen M; Liu B; Xiao J; Yang Y; Zhang Y
    Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
    Ooki A; Maleki Z; Tsay JJ; Goparaju C; Brait M; Turaga N; Nam HS; Rom WN; Pass HI; Sidransky D; Guerrero-Preston R; Hoque MO
    Clin Cancer Res; 2017 Nov; 23(22):7141-7152. PubMed ID: 28855354
    [No Abstract]   [Full Text] [Related]  

  • 19. A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Liljedahl H; Karlsson A; Oskarsdottir GN; Salomonsson A; Brunnström H; Erlingsdottir G; Jönsson M; Isaksson S; Arbajian E; Ortiz-Villalón C; Hussein A; Bergman B; Vikström A; Monsef N; Branden E; Koyi H; de Petris L; Patthey A; Behndig AF; Johansson M; Planck M; Staaf J
    Int J Cancer; 2021 Jan; 148(1):238-251. PubMed ID: 32745259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
    Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
    J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.